Partner With Us NRI

RPG Life Sciences Ltd share Price

Company details

6M Return -6.38%
1Y Return 19.90%
Mkt Cap.(Cr) 1,160.21
Volume 616
Div Yield 1.36%
OI Chg %
Volume 616

Open Free Trading Account Online with ICICIDIRECT

RPG Life Sciences Ltd.

Q3FY23 Quarterly Result Announced for RPG Life Sciences Ltd.

Pharmaceuticals firm RPG Life Sciences announced Q3FY23 results:

Q3FY23 & 9MFY23:

  • RPG Life Sciences posted a jump in PBT by 25% YoY for Q3FY23, maintaining the upward trajectory in EBITDA margins, which improved from 21.4% to 22.8% YoY.
  • Revenue from operations at Rs 130.60 crores registered a growth of 13% YoY for Q3FY23. For 9MFY23 too, the company posted a jump in PBT by 25% YoY and recorded EBITDA margin expansion from 22.2% to 22.8% YoY.
  • Revenue from operations at Rs 394.32 crores registered a growth of 17% YoY for 9MFY23.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q3 FY23, Company maintained its upward trajectory of overall robust performance by posting yet another strong results despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by healthy 13% and 25% respectively YoY. EBITDA margin grew from 21.4% to 22.8% YoY.

Domestic Formulations business, the biggest contributor to company business, recorded robust growth both in value and volumes - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Our digitalization initiatives are showing strong traction. Salesforce productivity continues to register healthy upward momentum across business segments. International Formulations business has also shown robust growth while API business has also picked up growth momentum. Our relentless focus on achieving cost efficiencies in our operations, eye on sales hygiene, is helping us to consistently improve our margins. We are well on course to implement our Transformation Agenda to achieve our strategic goals.”


Result PDF

View Other Company Results



Operating Profit

Profit after Tax


Reserves and Surplus



Operating Profit

Profit after Tax




RPG Life Sciences Ltd Stocks COMPARISION


Equity Capital: 255.77 Cr FV: 8.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 22,948.47 4,147.77
LAST 3M 50,808.43 -11,347.14
LAST 6M 78,521.89 15,105.83
LAST 12M 169,956.63 -37,974.87

RPG Life Sciences Ltd Information

Stock PE (TTM)


Promoter Holding


Book Value







  • RPG Life Sciences Ltd is engaged in the development, manufacture, and marketing of bulk drugs and formulations primarily in India. The company provides active pharmaceutical ingredients and generic formulations, as well as medications for critical and chronic ailments. They also manufacture life saving drugs using biotechnology. The company is having research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. They are having TGA (Aus) and MHRA (UK) approved facilities at Thane in Maharashtra and Ankleshwar in Gujarat. RPG Life Sciences Ltd was incorporated on March 29, 2007 with the name RPG Pharmaceuticals Ltd. During the year 2007-08, as per the scheme of arrangement, the company acquired the pharmaceuticals business of Brabourne Enterprises Ltd along with all assets and liabilities pertaining to that business with effect from April 2, 2007 (the appointed date). In February 13, 2008, the name of the company was subsequently changed to RPG Life Sciences Ltd. During the year 2008-09, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes. They launched an oncology drug namely Exemestane. Also, they launched new products, namely Nufex Beta, Qugyl-O & Immunotec. In June 10, 2008, the equity shares of the company were listed on BSE and NSE with effect from June 10, 2008. In July 2008, the company commenced production in the new high capacity fermenters. During the year 2009-10, the company strengthened their product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. The new products launched during the year were Demator, Sizomax, Mela, Exinia and Mofetyl S. They launched a new immunosuppressant product, Sirolimus, during the year. Also, they introduced 11 new products across several therapeutic segments. The company plans to launch six new bulk drugs and two existing products in new markets. They also plan to file DMFs for several products in regulated and semi regulated markets. The company is having plans to set up dedicated divisions with their own sales force and portfolio of brands that will drive the business in therapeutic areas like oncology, psychiatry and diabetology.

Registered Address

RPG House, 463 Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030

Tel : 91-022-24981650
Email : info:rpglifesciences.com
Website : http://www.rpglifesciences.com


Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 8
Market Lot Equity Shares : 1
BSE Code : 532983
Book Closure Date (Month) :
BSE Group : B
ISIN : INE105J01010

FAQ’s on RPG Life Sciences Ltd Shares

You can buy RPG Life Sciences Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy RPG Life Sciences Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Mar 27, 2023 04:01 PM the closing price of RPG Life Sciences Ltd was ₹ 701.50.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 27, 2023 04:01 PM, the market cap of RPG Life Sciences Ltd stood at ₹ 1,160.21.

The latest PE ratio of RPG Life Sciences Ltd as of Mar 27, 2023 04:01 PM is 17.98

The latest PB ratio of RPG Life Sciences Ltd as of Mar 27, 2023 04:01 PM is 0.24

The 52-week high of RPG Life Sciences Ltd is ₹ 1,012.45 while the 52-week low is ₹ 451.80

Download Our App

market app
market app